{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:35Z","timestamp":1792790495753,"version":"4.5.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1097\/inf.0000000000000299","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T14:33:16Z","timestamp":1394548396000},"page":"e198-e206","source":"Crossref","is-referenced-by-count":21,"title":["Deoxycholate Amphotericin B and Nephrotoxicity in the Pediatric Setting"],"prefix":"10.1097","volume":"33","author":[{"given":"David F.","family":"Bes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda T.","family":"Rosanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Sberna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Arrizurieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-13-20210202","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2165\/00002018-199005020-00003","article-title":"Amphotericin B nephrotoxicity.","volume":"5","author":"Sabra","year":"1990","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"R4-13-20210202","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","article-title":"Overview of lipid formulations of amphotericin B.","volume":"49","author":"Dupont","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"R5-13-20210202","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00043426-200407000-00004","article-title":"Amphotericin B nephrotoxicity in children.","volume":"26","author":"Goldman","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"R8-13-20210202","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003495-200969030-00010","article-title":"Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.","volume":"69","author":"Moem","year":"2009","journal-title":"Drugs"},{"key":"R10-13-20210202","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1086\/313555","article-title":"Estimating the true cost of amphotericin B.","volume":"29","author":"Rex","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R11-13-20210202","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new gold standard.","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R12-13-20210202","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis.","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin Infect Dis"},{"key":"R16-13-20210202","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1128\/AAC.43.6.1417","article-title":"Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.","volume":"43","author":"Nath","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-13-20210202","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jac\/37.6.1165","article-title":"Amphotericin B intralipid formulation: stability and particle size.","volume":"37","author":"Ranchere","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"R18-13-20210202","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/jac\/31.5.806","article-title":"Toxicity of amphotericin B emulsion formulations.","volume":"31","author":"Washington","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"R19-13-20210202","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00006454-200006000-00015","article-title":"Lipid amphotericin preparations.","volume":"19","author":"Williams","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"R20-13-20210202","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1086\/653606","article-title":"Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.","volume":"51","author":"Hamill","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R21-13-20210202","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5546\/aap.2012.46","article-title":"Advantages and drawbacks of amphotericin formulations in children: literature review.","volume":"110","author":"Bes","year":"2012","journal-title":"Arch Argent Pediatr"},{"key":"R22-13-20210202","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4067\/S0716-10182004000400006","article-title":"Tratamiento de infecciones fungicas sistemicas. III parte: Anfotericina B, aspectos farmacoeconomicos y decisiones terapeuticas.","volume":"21","author":"Fica","year":"2004","journal-title":"Rev Chil Infect"},{"key":"R23-13-20210202","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s11096-012-9654-y","article-title":"Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions.","volume":"34","author":"Horwitz","year":"2012","journal-title":"Int J Clin Pharm"},{"key":"R24-13-20210202","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/0091270007301799","article-title":"Pharmacological risk factors for amphotericin B nephrotoxicity in children.","volume":"47","author":"Goldman","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"R25-13-20210202","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients.","volume":"98","author":"Prentice","year":"1997","journal-title":"Br J Haematol"},{"key":"R26-13-20210202","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e3181af6201","article-title":"Nephrotoxicity associated with amphotericin B deoxycholate in neonates.","volume":"28","author":"Lee","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R27-13-20210202","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00043426-200005000-00009","article-title":"Use of amphotericin B colloidal dispersion in children.","volume":"22","author":"Sandler","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"R28-13-20210202","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/INF.0b013e31825d649a","article-title":"Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.","volume":"31","author":"Dutta","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R29-13-20210202","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.ki.5002231","article-title":"Modified RIFLE criteria in critically ill children with acute kidney injury.","volume":"71","author":"Akcan-Arikan","year":"2007","journal-title":"Kidney Int"},{"key":"R30-13-20210202","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia.","volume":"27","author":"White","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R31-13-20210202","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"R32-13-20210202","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1542\/peds.113.6.e608","article-title":"Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants.","volume":"113","author":"Holler","year":"2004","journal-title":"Pediatrics"},{"key":"R33-13-20210202","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1086\/313748","article-title":"Introduction to antifungal drugs.","volume":"30","author":"Dismukes","year":"2000","journal-title":"Clin Infect Dis"},{"key":"R34-13-20210202","first-page":"199","article-title":"Amphotericin B nephrotoxicity.","volume":"38","author":"Raymond","year":"1988","journal-title":"Am Fam Physician"},{"key":"R35-13-20210202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R36-13-20210202","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00431-012-1758-9","article-title":"Antifungal therapy in children: an update.","volume":"172","author":"Cecinati","year":"2013","journal-title":"Eur J Pediatr"},{"key":"R38-13-20210202","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s00467-007-0721-x","article-title":"Nephrotoxicity as a cause of acute kidney injury in children.","volume":"23","author":"Patzer","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"R39-13-20210202","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1034\/j.1600-0773.2001.d01-99.x","article-title":"Role of humoral mediators in, and influence of a liposomal formulation on, acute amphotericin B nephrotoxicity.","volume":"88","author":"Sabra","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"R40-13-20210202","first-page":"F1","article-title":"Nephrotoxic acute renal failure due to common drugs.","volume":"241","author":"Porter","year":"1981","journal-title":"Am J Physiol"},{"key":"R41-13-20210202","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1172\/JCI115240","article-title":"Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats.","volume":"87","author":"Sawaya","year":"1991","journal-title":"J Clin Invest"},{"key":"R42-13-20210202","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1681\/ASN.V62154","article-title":"Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.","volume":"6","author":"Sawaya","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R43-13-20210202","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/ki.1992.229","article-title":"Direct amphotericin B-mediated tubular toxicity: assessments of selected cytoprotective agents.","volume":"41","author":"Zager","year":"1992","journal-title":"Kidney Int"},{"key":"R44-13-20210202","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/AAC.14.2.270","article-title":"Erythropoietin concentration in amphotericin B-induced anemia.","volume":"14","author":"MacGregor","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"R45-13-20210202","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R47-13-20210202","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jac\/43.2.267","article-title":"Risk factors for amphotericin B-induced nephrotoxicity.","volume":"43","author":"Luber","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"R49-13-20210202","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/infdis\/155.4.766","article-title":"Pharmacokinetics of amphotericin B in infants and children.","volume":"155","author":"Starke","year":"1987","journal-title":"J Infect Dis"},{"key":"R51-13-20210202","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1128\/AAC.33.11.1989","article-title":"Pharmacokinetics of amphotericin B in children.","volume":"33","author":"Benson","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"R52-13-20210202","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.13.2.271","article-title":"Amphotericin B pharmacokinetics in humans.","volume":"13","author":"Atkinson","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"R54-13-20210202","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/ebch.631","article-title":"Commentaries on Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections with a response from the review authors.","volume":"5","author":"Groll","year":"2010","journal-title":"Evid Based Child Health"},{"key":"R55-13-20210202","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1128\/CMR.12.2.310","article-title":"Aspergillus fumigatus and aspergillosis.","volume":"12","author":"Latge","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"R57-13-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00467-005-2105-4","article-title":"Ontogeny of drug elimination by the human kidney.","volume":"21","author":"Chen","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R58-13-20210202","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/infdis\/140.3.329","article-title":"Excretion pathways of amphotericin B.","volume":"140","author":"Craven","year":"1979","journal-title":"J Infect Dis"},{"key":"R60-13-20210202","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.0306-5251.2001.01496.x","article-title":"Population pharmacokinetics of amphotericin B in children with malignant diseases.","volume":"52","author":"Nath","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R61-13-20210202","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(81)92597-6","article-title":"Sodium depletion enhances nephrotoxicity of amphotericin B.","volume":"1","author":"Feely","year":"1981","journal-title":"Lancet"},{"key":"R62-13-20210202","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1001\/archinte.1988.00380110049010","article-title":"Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation.","volume":"148","author":"Branch","year":"1988","journal-title":"Arch Intern Med"},{"key":"R63-13-20210202","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0022-3565(25)32172-5","article-title":"The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity.","volume":"214","author":"Gerkens","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"R64-13-20210202","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.1991.214","article-title":"Effect of salt supplementation on amphotericin B nephrotoxicity.","volume":"40","author":"Llanos","year":"1991","journal-title":"Kidney Int"},{"key":"R65-13-20210202","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00467-008-1050-4","article-title":"Influence of sodium intake on Amphotericin B-induced nephrotoxicity among extremely premature infants.","volume":"24","author":"Turcu","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"R66-13-20210202","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Jr., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Disease Society of America.","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R67-13-20210202","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1185\/03007995.2010.487793","article-title":"Invasive aspergillosis in pediatric patients.","volume":"26","author":"Steinbach","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"R70-13-20210202","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/j.1469-0691.2010.03334.x","article-title":"Update on antifungal agents for paediatric patients.","volume":"16","author":"Groll","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"R71-13-20210202","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/INF.0b013e31828745b2","article-title":"Update on antifungal resistance in children: epidemiology and recommendations.","volume":"32","author":"Verweij","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R72-13-20210202","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R73-13-20210202","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.2012.09156.x","article-title":"A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children.","volume":"158","author":"Caselli","year":"2012","journal-title":"Br J Haematol"},{"key":"R74-13-20210202","first-page":"57","article-title":"Pediatric antifungal therapy. Part I: focus on febrile neutropenia, invasive aspergillosis, combination antifungal therapy and invasive candidiasis in immunocompromised pediatric patients.","volume":"62","author":"Allen","year":"2010","journal-title":"Minerva Pediatr"},{"key":"R77-13-20210202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1586\/14787210.3.2.167","article-title":"Liposomal amphotericin B: clinical experience and perspectives.","volume":"3","author":"Gibbs","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R78-13-20210202","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.inf.0000153183.51258.b8","article-title":"Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.","volume":"24","author":"Wiley","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"R79-13-20210202","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/INF.0b013e3181e7db7f","article-title":"Risk factors associated with invasive fungal disease in children with cancer and febrile neutropenia: a prospective multicenter evaluation.","volume":"29","author":"Villarroel","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"R80-13-20210202","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1439-0507.2007.01449.x","article-title":"Invasive aspergillosis in a paediatric haematology department: a 15-year review.","volume":"51","author":"Crassard","year":"2008","journal-title":"Mycoses"},{"key":"R84-13-20210202","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1542\/peds.2011-0415","article-title":"Hypotonic versus isotonic maintenance fluids after surgery for children: a randomized controlled trial.","volume":"128","author":"Choong","year":"2011","journal-title":"Pediatrics"},{"key":"R86-13-20210202","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/00001432-200412000-00005","article-title":"Clinical utility of antifungal pharmacokinetics and pharmacodynamics.","volume":"17","author":"Andes","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"R87-13-20210202","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00148581-200709030-00001","article-title":"Drug-induced nephrotoxicity in children: pharmacologically based prevention of long-term impairment.","volume":"9","author":"Koren","year":"2007","journal-title":"Paediatr Drugs"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000000299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T01:21:37Z","timestamp":1746148897000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201408000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000000299","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}